Regeneron Hypes New Eczema Drug Dupixent In 1Q
Executive Summary
Analysts have significantly upped their 2017 sales forecasts for Regeneron and Sanofi's recently launched eczema drug Dupixent on the back of a strong first few weeks on the market and positive vibes from Regeneron – which held a spotlight firmly on its new therapy during its May 4 first quarter earnings call.
You may also be interested in...
Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs
Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.
Infographic: Top 100 Pharma Companies
The Scrip 100 universe gathers FY2021 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.